STN- Structure Search 10/25/05

10/743,950

=> d ibib abs hitstr 1-18

L6 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:673254 CAPLUS
DOCUMENT NUMBER: 143:153074
TITLE: Preparation of mono- and bis-thioethers for cholesterol management
INVENTOR(S): Basseux, Jean-Louis; Oniciu, Carmen Daniela
PATENT ASSIGNEE(S): Esperion Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 255 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068418	A1	20050728	WO 2003-US41612	20031224

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: WO 2003-US41612 20031224

AB Mono- and bis-thioethers W1-Zm-S-G-S-Zm-W2 [I; Z = CH2, CH=CH, phenyl; m = 1-9; G = (CH2)2-4, CH2CH=CHCH2, etc.; W1-2 = divalent alkyl, etc.], and W1-(CH2)n-C(R1)(R2)-(CH2)m-S-(CH2)m-C(R11)(R12)-(CH2)n-W2 (II; variables described in claims) are claimed. Although the methods of preparation are not claimed, .apprx.10 example prepns. are included. For instance, 5-[2-(4-carboxy-4-methylpentylsulfanyl)ethylsulfanyl]-2,2-dimethylpentanoic acid is prepared in 3 steps from Et 5-bromo-2,2-dimethylpentanoate. I-II are useful for treating and preventing cardiovascular diseases, dyslipidemias, dyslipoproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound I-II are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. Effects of 3 monosulfides (examples of II) on non-HDL cholesterol, HDL cholesterol, triglyceride levels, glycemic control indicators and body weight control in obese female Zucker rats are tabulated.

IT **412932-76-4P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of mono- and bis-thioethers for cholesterol management)

RN 412932-76-4 CAPLUS
CN Butanoic acid, 4,4'-[1,3-propanediylbis(thio)]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



IT **412937-64-5P 412937-88-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of mono- and bis-thioethers for cholesterol management)
RN 412937-64-5 CAPLUS
CN Pentanoic acid, 5,5'-[1,2-ethanediylbis(thio)]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 412937-88-3 CAPLUS
CN Butanoic acid, 4,4'-[1,3-propanediylbis(thio)]bis[2,2-dimethyl-, disodium salt (9CI) (CA INDEX NAME)



●2 Na

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:451346 CAPLUS
DOCUMENT NUMBER: 142:481741
TITLE: Preparation of sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
INVENTOR(S): Dasseux, Jean-Louis; Oniciu, Carmen Daniela
PATENT ASSIGNEE(S): Esperion Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 251 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005047236	A1	20050526	WO 2003-US41614	20031224

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,

ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004122091 A1 20040624 US 2003-702701 20031107
PRIORITY APPLN. INFO.: US 2003-702701 A 20031107
US 2000-239105P P 20001011
US 2001-976899 A3 20011011

AB Title compds. W1ZmSOGSOZmW2 (I) [wherein Z = independently CH2, CH:CH, or C6H4; m = independently 1-9; when Z = C6H4, m = 1; G = (CH2)x, CH2CH:CHCH2, CH:CH, CH2C6H4CH2, or C6H4; x = 2-4; W1 and W2 = independently CR1R2(CH2)nY, tetrahydro(oxo)pyranyl(oxy), oxooxetanyl, tetrahydrooxofuranyl, etc.; CR1R2(CH2)cCR3R4(CH2)nY, or CR1R2(CH2)cV; n = 0-4; c = 1-2; R1 and R2 = independently alkyl, alkenyl, alkynyl, Ph, or benzyl; or when one or both of W1 and W2 = CR1R2(CH2)cCR3R4Y, then R1 and R2 can both be H; R3 = H, alkyl, alkenyl, alkynyl, alkoxy, Ph, benzyl, Cl, Br, NO2, or CF3; R4 = OH, alkyl, alkenyl, alkynyl, alkoxy, Ph, benzyl, Cl, Br, CN, NO2, or CF3; Y = OH, CO2H, CHO, CO2R5, SO3H, mono-, di-, or triphosphate, dioxo- or dithioxohexahydrothieno[3,2-c]pyridinyl, sulfamoyl, tetrazolyl, hydroxyoxazolyl, hydroxypyranonyl, substituted imidazolidinedionyl, etc.; R5 = (un)substituted alkyl, alkenyl, alkynyl, Ph, or benzyl] were prepared as peroxisome proliferator activated receptor (PPAR) antagonists for treatment and prevention of cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders. I are also useful for treating and preventing Alzheimer's Disease, Syndrome X, PPAR-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer inflammation, and impotence. For example, 6-(5,5-dimethyl-6-hydroxyhexylsulfanyl)-2,2-dimethylhexan-1-ol was oxidized to 6-(5,5-dimethyl-6-hydroxyhexane-1-sulfinyl)-2,2-dimethylhexan-1-ol (quant.) using H2O2 in glacial AcOH. The latter increased reduced serum triglycerides in female obese Zucker rats by 48% and 42% after 1 and 2 wk of treatment. Although non-HDL cholesterol increased by 38% and 62%, a marked increase in HDL cholesterol of 2.2-fold and 3.1-fold after one and two weeks of treatment, resp., resulted in an unexpectedly beneficial increased ratio of HDL/non-HDL cholesterol from 2.70 (pretreatment) to 3.84 and 4.97. In certain embodiments, I may be administered in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

IT **412951-74-7P 412951-75-8P 412951-76-9P**
412951-77-0P 412951-78-1P 412951-79-2P
412951-80-5P 412951-81-6P 412951-82-7P
412951-83-8P 412951-84-9P 412951-85-0P
412951-86-1P 412951-87-2P 412951-88-3P
412951-89-4P 412951-90-7P 412951-91-8P
412951-92-9P 412951-93-0P 412951-94-1P
412951-95-2P 412951-96-3P 412951-97-4P
412951-98-5P 412951-99-6P 412952-00-2P
412952-01-3P 412952-02-4P 412952-03-5P
412952-04-6P 412952-05-7P 412952-06-8P
412952-07-9P 412952-08-0P 412952-09-1P
412952-10-4P 412952-11-5P 412952-12-6P
412952-13-7P 412952-14-8P 412952-15-9P
412952-16-0P 412952-17-1P 412952-18-2P
412952-19-3P 412952-20-6P 412952-21-7P
412952-22-8P 412952-23-9P 412952-24-0P
412952-25-1P 412952-26-2P 412952-27-3P
412952-28-4P 412952-29-5P 412952-30-8P
412952-31-9P 412952-32-0P 412952-33-1P
412952-34-2P 412952-35-3P 412952-36-4P
412952-37-5P 412952-38-6P 412952-39-7P
412952-40-0P 412952-41-1P 412952-42-2P
412952-43-3P 412952-44-4P 412952-45-5P
412952-47-7P 412952-49-9P 412952-51-3P
412952-52-4P 412952-53-5P 412952-54-6P
412952-55-7P 412952-56-8P 412952-57-9P

412952-58-0P 412952-59-1P 412952-60-4P
412952-61-5P 412952-62-6P 412952-63-7P
412952-64-8P 412952-65-9P 412952-66-0P
412952-67-1P 412952-68-2P 412952-69-3P
412952-70-6P 412952-71-7P 412952-72-8P
412952-73-9P 412952-74-0P 412952-75-1P
412952-76-2P 412952-77-3P 412952-78-4P
412952-79-5P 412952-80-8P 412952-81-9P
412952-82-0P 412952-83-1P 412952-84-2P
412952-85-3P 412952-86-4P 412952-87-5P
412952-88-6P 412952-89-7P 412952-90-0P
412952-91-1P 412952-92-2P 412952-93-3P
412952-94-4P 412952-95-5P 412952-96-6P
412952-97-7P 412952-98-8P 412952-99-9P
412953-00-5P 412953-01-6P 412953-02-7P
412953-03-8P 412953-04-9P 412953-05-0P
412953-06-1P 412953-07-2P 412953-08-3P
412953-09-4P 412953-10-7P 412953-11-8P
412953-12-9P 412953-13-0P 412953-14-1P
412953-15-2P 412953-16-3P 412953-17-4P
412953-18-5P 412953-19-6P 412953-20-9P
412953-21-0P 412953-22-1P 412953-23-2P
412953-24-3P 412953-26-5P 412953-28-7P
412953-29-8P 412953-30-1P 412953-31-2P
412953-32-3P 412953-33-4P 412953-34-5P
412953-35-6P 412953-36-7P 412953-37-8P
412953-38-9P 412953-39-0P 412953-40-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)

RN 412951-74-7 CAPLUS
CN 2-Butanol, 4,4'-[1,3-propanediylbis(sulfinyl)]bis[2-methyl- (9CI) (CA INDEX NAME)



RN 412951-75-8 CAPLUS
CN 1-Butanol, 4,4'-[1,3-propanediylbis(sulfinyl)]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 412951-76-9 CAPLUS
CN Butanoic acid, 4,4'-[1,3-propanediylbis(sulfinyl)]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 412953-40-3 CAPLUS
CN 1-Pentanol, 5,5'-[1,2-ethanediylbis(sulfinyl)]bis[3,3-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:362049 CAPLUS
DOCUMENT NUMBER: 142:417191
TITLE: Drug administration method and formulations for control of renal transporter-mediated drug transport
INVENTOR(S): Kawai, Keiichi; Takamura, Tokuhito; Shikano, Naoto; Nishii, Ryuichi
PATENT ASSIGNEE(S): Nihon Mediphysics Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005112750	A2	20050428	JP 2003-347116	20031006
PRIORITY APPLN. INFO.:			JP 2003-347116	20031006

AB Renal transporter-mediated excretion of the 1st drugs (e.g., radiodiagnostic agents or radiopharmaceuticals) are controlled by previous, simultaneous, or subsequent administration of the 2nd drugs comprising inhibitors for the renal transporters. The drug formulations comprise the 1st and 2nd drugs placed in sep. containers. The transport of 99mTc-labeled mercaptoacetylglycylglycylglycine (Tc-MAG3) to the bladder within 15 min after administration to mice was suppressed and its accumulation in organs was increased by administering probenecid (20 mg/kg i.v.) before Tc-MAG3 administration.

IT **14344-49-1D**, radiolabeled
RL: DGN (Diagnostic use); PKT (Pharmacokinetics); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(control of renal transporter-mediated drug excretion by administration of renal transporter inhibitors)
RN 14344-49-1 CAPLUS
CN L-Cysteine, S,S'-1,2-ethanediylbis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



inventors

L6 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:78257 CAPLUS
DOCUMENT NUMBER: 142:155552
TITLE: Preparation of sulfide and disulfide compounds for cholesterol management
INVENTOR(S): Dasseux, Jean-louis Henri; Oniciu, Daniela Carmen
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 137 pp., Cont.-in-part of U.S. Ser. No. 976,898.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005020694	A1	20050127	US 2003-743950	20031224
US 2002077316	A1	20020620	US 2001-976898	20011011
US 6703422	B2	20040309		
PRIORITY APPLN. INFO.:			US 2001-976898 A2	20011011
			US 2000-239231P P	20001011
OTHER SOURCE(S):		MARPAT 142:155552		

AB Title compds. W1-Zm-S-G-S-Zm-W2 [Z = CH2, CH=CH, phenyl; m = 1-9; G = (CH2)2-4, CH2CH=CHCH2, etc.; W1-2 = divalent alkyl, etc.; I] are prepared For instance, 5-[2-(4-carboxy-4-methylpentylsulfanyl)ethylsulfanyl]-2,2-dimethylpentanoic acid is prepared in 3 steps from Et 5-bromo-2,2-dimethylpentanoate. Compds. of the invention are useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound I are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compds., compns., and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

IT **412932-76-4P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of sulfide and disulfide compds. for cholesterol management)
RN 412932-76-4 CAPLUS
CN Butanoic acid, 4,4'-[1,3-propanediylbis(thio)]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



IT **412937-64-5P 412937-88-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfide and disulfide compds. for cholesterol management)
RN 412937-64-5 CAPLUS
CN Pentanoic acid, 5,5'-[1,2-ethanediylbis(thio)]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 412937-88-3 CAPLUS
CN Butanoic acid, 4,4'-[1,3-propanediylbis(thio)]bis[2,2-dimethyl-, disodium salt (9CI) (CA INDEX NAME)



●2 Na

L6 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:857199 CAPLUS
DOCUMENT NUMBER: 141:331803
TITLE: Preparation of sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
INVENTOR(S): Dasseux, Jean-Louis Henri; Oniciu, Daniela Carmen
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 142 pp., Cont.-in-part of U.S. Ser. No. 976,899.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004204502	A1	20041014	US 2003-744401	20031224
US 2003022865	A1	20030130	US 2001-976899	20011011
US 6673780	B2	20040106		

PRIORITY APPLN. INFO.: US 2001-976899 A2 20011011
US 2000-239105P P 20001011
OTHER SOURCE(S): MARPAT 141:331803
AB Title compds. W1ZmSOGSOZmW2 (I) [wherein Z = independently CH2, CH:CH, or C6H4; m = independently 1-9; when Z = C6H4, m = 1; G = (CH2)x, CH2CH:CHCH2, CH:CH, CH2C6H4CH2, or C6H4; x = 2-4; W1 and W2 = independently CR1R2(CH2)nY, tetrahydro(oxo)pyranyl(oxy), oxooxetanyl,

tetrahydrooxofuranyl, etc.; CR1R2(CH2)cCR3R4(CH2)nY, or CR1R2(CH2)cV; n = 0-4; c = 1-2; R1 and R2 = independently alkyl, alkenyl, alkynyl, Ph, or benzyl; or when one or both of W1 and W2 = CR1R2(CH2)cCR3R4Y, then R1 and R2 can both be H; R3 = H, alkyl, alkenyl, alkynyl, alkoxy, Ph, benzyl, Cl, Br, NO2, or CF3; R4 = OH, alkyl, alkenyl, alkynyl, alkoxy, Ph, benzyl, Cl, Br, CN, NO2, or CF3; Y = OH, CO2H, CHO, CO2R5, SO3H, mono-, di-, or triphosphate, dioxo- or dithioxohexahydrothieno[3,2-c]pyridinyl, sulfamoyl, tetrazolyl, hydroxyoxazolyl, hydroxypyranonyl, substituted imidazolidinedionyl, etc.; R5 = (un)substituted alkyl, alkenyl, alkynyl, Ph, or benzyl] were prepared as peroxisome proliferator activated receptor (PPAR) antagonists for treatment and prevention of cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders. I are also useful for treating and preventing Alzheimer's Disease, Syndrome X, PPAR-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer inflammation, and impotence. For example, 6-(5,5-dimethyl-6-hydroxyhexylsulfanyl)-2,2-dimethylhexan-1-ol was oxidized to 6-(5,5-dimethyl-6-hydroxyhexane-1-sulfinyl)-2,2-dimethylhexan-1-ol (quant.) using H2O2 in glacial AcOH. The latter increased reduced serum triglycerides in female obese Zucker rats by 48% and 42% after 1 and 2 wk of treatment. Although non-HDL cholesterol increased by 38% and 62%, a marked increase in HDL cholesterol of 2.2-fold and 3.1-fold after one and two weeks of treatment, resp., resulted in an unexpectedly beneficial increased ratio of HDL/non-HDL cholesterol from 2.70 (pretreatment) to 3.84 and 4.97. In certain embodiments, I may be administered in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

IT **412951-74-7P 412951-75-8P 412951-76-9P**
412951-77-0P 412951-78-1P 412951-79-2P
412951-80-5P 412951-81-6P 412951-82-7P
412951-83-8P 412951-84-9P 412951-85-0P
412951-86-1P 412951-87-2P 412951-88-3P
412951-89-4P 412951-90-7P 412951-91-8P
412951-92-9P 412951-93-0P 412951-94-1P
412951-95-2P 412951-96-3P 412951-97-4P
412951-98-5P 412951-99-6P 412952-00-2P
412952-01-3P 412952-02-4P 412952-03-5P
412952-04-6P 412952-05-7P 412952-06-8P
412952-07-9P 412952-08-0P 412952-09-1P
412952-10-4P 412952-11-5P 412952-12-6P
412952-13-7P 412952-14-8P 412952-15-9P
412952-16-0P 412952-17-1P 412952-18-2P
412952-19-3P 412952-20-6P 412952-21-7P
412952-22-8P 412952-23-9P 412952-24-0P
412952-25-1P 412952-26-2P 412952-27-3P
412952-28-4P 412952-29-5P 412952-30-8P
412952-31-9P 412952-32-0P 412952-33-1P
412952-34-2P 412952-35-3P 412952-36-4P
412952-37-5P 412952-38-6P 412952-39-7P
412952-40-0P 412952-41-1P 412952-42-2P
412952-43-3P 412952-44-4P 412952-45-5P
412952-47-7P 412952-49-9P 412952-51-3P
412952-52-4P 412952-53-5P 412952-54-6P
412952-55-7P 412952-56-8P 412952-57-9P
412952-58-0P 412952-59-1P 412952-60-4P
412952-61-5P 412952-62-6P 412952-63-7P
412952-64-8P 412952-65-9P 412952-66-0P
412952-67-1P 412952-68-2P 412952-69-3P
412952-70-6P 412952-71-7P 412952-72-8P
412952-73-9P 412952-74-0P 412952-75-1P
412952-76-2P 412952-77-3P 412952-78-4P
412952-79-5P 412952-80-8P 412952-81-9P
412952-82-0P 412952-83-1P 412952-84-2P
412952-85-3P 412952-86-4P 412952-87-5P

412952-88-6P 412952-89-7P 412952-90-0P
412952-91-1P 412952-92-2P 412952-93-3P
412952-94-4P 412952-95-5P 412952-96-6P
412952-97-7P 412952-98-8P 412952-99-9P
412953-00-5P 412953-01-6P 412953-02-7P
412953-03-8P 412953-04-9P 412953-05-0P
412953-06-1P 412953-07-2P 412953-08-3P
412953-09-4P 412953-10-7P 412953-11-8P
412953-12-9P 412953-13-0P 412953-14-1P
412953-15-2P 412953-16-3P 412953-17-4P
412953-18-5P 412953-19-6P 412953-20-9P
412953-21-0P 412953-22-1P 412953-23-2P
412953-24-3P 412953-26-5P 412953-28-7P
412953-29-8P 412953-30-1P 412953-31-2P
412953-32-3P 412953-33-4P 412953-34-5P
412953-35-6P 412953-36-7P 412953-37-8P
412953-38-9P 412953-39-0P 412953-40-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)

RN 412951-74-7 CAPLUS
CN 2-Butanol, 4,4'-[1,3-propanediylbis(sulfinyl)]bis[2-methyl- (9CI) (CA INDEX NAME)



RN 412951-75-8 CAPLUS
CN 1-Butanol, 4,4'-[1,3-propanediylbis(sulfinyl)]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 412951-76-9 CAPLUS
CN Butanoic acid, 4,4'-[1,3-propanediylbis(sulfinyl)]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 412951-77-0 CAPLUS
CN Butanal, 4,4'-[1,3-propanediylbis(sulfinyl)]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:252374 CAPLUS
DOCUMENT NUMBER: 140:259143
TITLE: Preparation for controlling binding of drug to plasma protein
INVENTOR(S): Kawai, Keiichi; Takamura, Norito
PATENT ASSIGNEE(S): Nihon Medi-Physics Co., Ltd., Japan
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024188	A1	20040325	WO 2003-JP11516	20030909

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2002-267010 A 20020912

AB It is intended to provide a preparation controlling the concentration of an active ingredient, which has binding affinity for a plasma protein, released in the blood, characterized in that, in the administration of the active ingredient having binding affinity for a plasma protein, a preparation containing one or more amino acids having binding affinity for the same plasma protein as the above-described active ingredient does is administered simultaneously with the active ingredient or before or after the administration thereof to thereby control the binding of the active ingredient to the plasma protein, and a method of administering the preparation The effects of amino acids including Trp, Asp, Leu, Met, proteamin 12X, N-acetyltryptophan on regulation of binding of 123I-N-isopropyl-p-iodoamphetamine to plasma protein were examined

IT **14344-49-1D**, radiolabeled
RL: DGN (Diagnostic use); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(compns. containing amino acids for controlling binding of drug to plasma protein)

RN 14344-49-1 CAPLUS
CN L-Cysteine, S,S'-1,2-ethanediylbis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Inventor?

L6 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:293609 CAPLUS
DOCUMENT NUMBER: 136:325530
TITLE: Aliphatic, aromatic, and heterocyclic sulfide and disulfide compounds and compositions for cholesterol management and related uses
INVENTOR(S): Dasseux, Jean-Louis H.; Oniciu, Carmen Daniela
PATENT ASSIGNEE(S): Esperion Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 278 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030884	A2	20020418	WO 2001-US31869	20011011
WO 2002030884	A3	20030925		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2425674	AA	20020418	CA 2001-2425674	20011011
AU 2002011666	A5	20020422	AU 2002-11666	20011011
EP 1363879	A2	20031126	EP 2001-979734	20011011
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004532799	T2	20041028	JP 2002-534272	20011011

PRIORITY APPLN. INFO.: US 2000-239231P P 20001011
WO 2001-US31869 W 20011011
OTHER SOURCE(S): MARPAT 136:325530
GI



I

AB The invention relates to novel sulfide and disulfide compds., compns.



RN 412932-75-3 CAPLUS
CN 1-Butanol, 4,4'-[1,3-propanediylbis(thio)]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 412932-76-4 CAPLUS
CN Butanoic acid, 4,4'-[1,3-propanediylbis(thio)]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 412932-77-5 CAPLUS
CN Butanal, 4,4'-[1,3-propanediylbis(thio)]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 412932-78-6 CAPLUS
CN Butanoic acid, 4,4'-[1,3-propanediylbis(thio)]bis[2,2-dimethyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 412932-79-7 CAPLUS
CN Butanoic acid, 4,4'-[1,3-propanediylbis(thio)]bis[2,2-dimethyl-, diphenyl ester (9CI) (CA INDEX NAME)



RN 412932-80-0 CAPLUS
CN Butanoic acid, 4,4'-[1,3-propanediylbis(thio)]bis[2,2-dimethyl-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 412932-81-1 CAPLUS
CN 2-Butanesulfonic acid, 4,4'-[1,3-propanediylbis(thio)]bis[2-methyl- (9CI) (CA INDEX NAME)



RN 412932-82-2 CAPLUS
CN 2-Oxa-6,10-dithia-1-phosphatetradecan-13-ol, 1,1-dihydroxy-3,3,13-trimethyl-, 13-(dihydrogen phosphate), 1-oxide (9CI) (CA INDEX NAME)



RN 412932-83-3 CAPLUS
CN Thieno[3,2-c]pyridine-4,6(2H,5H)-dione, 5,5'-[1,3-propanediylbis[thio(1,1-dimethyl-3,1-propanediyl)]]bis[3,3a-dihydro- (9CI) (CA INDEX NAME)



RN 412932-84-4 CAPLUS
CN Thieno[3,2-c]pyridine-4,6(2H,5H)-dithione, 5,5'-[1,3-propanediylbis[thio(1,1-dimethyl-3,1-propanediyl)]]bis[3,3a-dihydro- (9CI) (CA INDEX NAME)



RN 412932-85-5 CAPLUS
CN Butanamide, 4,4'-[1,3-propanediylbis(thio)]bis[N-cyano-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 412932-86-6 CAPLUS
CN Phosphoramidic acid, 1,3-propanediylbis[thio(1,1-dimethyl-3,1-propanediyl)] ester (9CI) (CA INDEX NAME)



RN 412932-87-7 CAPLUS
CN Phosphonamidic acid, P,P'-[1,3-propanediylbis[thio(1,1-dimethyl-3,1-propanediyl)]]bis- (9CI) (CA INDEX NAME)



RN 412932-88-8 CAPLUS
CN 1H-Tetrazole, 1,1'-[1,3-propanediylbis[thio(1,1-dimethyl-3,1-propanediyl)]]bis- (9CI) (CA INDEX NAME)



RN 412932-89-9 CAPLUS
CN 1H-Tetrazole, 5,5'-[1,3-propanediylbis[thio(1,1-dimethyl-3,1-propanediyl)]]bis- (9CI) (CA INDEX NAME)

RN 412932-99-1 CAPLUS
CN Pentanoic acid, 5,5'-[1,3-propanediylbis(thio)]bis[3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 412933-00-7 CAPLUS
CN Pentanal, 5,5'-[1,3-propanediylbis(thio)]bis[3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 412933-01-8 CAPLUS
CN Pentanoic acid, 5,5'-[1,3-propanediylbis(thio)]bis[3,3-dimethyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 412933-02-9 CAPLUS
CN Pentanoic acid, 5-[[3-[(3,3-dimethyl-4-oxo-4-phenoxybutyl)thio]propyl]thio]-3,3-dimethyl-, phenyl ester (9CI) (CA INDEX NAME)



RN 412933-03-0 CAPLUS
CN Pentanoic acid, 5-[[3-[[3,3-dimethyl-4-oxo-4-(phenylmethoxy)butyl]thio]propyl]thio]-3,3-dimethyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Ph

RN 412933-04-1 CAPLUS
CN 1-Butanesulfonic acid, 4,4'-[1,3-propanediylbis(thio)]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 412933-05-2 CAPLUS
CN 2-Oxa-7,11-dithia-1-phosphapentadecan-15-ol, 1,1-dihydroxy-4,4,14,14-tetramethyl-, 15-(dihydrogen phosphate), 1-oxide (9CI) (CA INDEX NAME)



RN 412933-06-3 CAPLUS
CN Thieno[3,2-c]pyridine-4,6(2H,5H)-dione, 5,5'-[1,3-propanediylbis[thio(2,2-dimethyl-4,1-butanediyl)]]bis[3,3a-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 412933-07-4 CAPLUS
CN Thieno[3,2-c]pyridine-4,6(2H,5H)-dithione, 5,5'-[1,3-propanediylbis[thio(2,2-dimethyl-4,1-butanediyl)]]bis[3,3a-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 412933-08-5 CAPLUS
CN Pentanamide, 5,5'-[1,3-propanediylbis(thio)]bis[N-cyano-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 412933-09-6 CAPLUS
CN Phosphoramidic acid, 1,3-propanediylbis[thio(2,2-dimethyl-4,1-butanediyl)] ester (9CI) (CA INDEX NAME)



RN 412933-10-9 CAPLUS
CN 1H-Tetrazole, 1,1'-[1,3-propanediylbis[thio(2,2-dimethyl-4,1-butanediyl)]]bis- (9CI) (CA INDEX NAME)



RN 412933-12-1 CAPLUS
CN 1H-Tetrazole, 5,5'-[1,3-propanediylbis[thio(2,2-dimethyl-4,1-butanediyl)]]bis- (9CI) (CA INDEX NAME)



RN 412933-41-6 CAPLUS
CN Butanoic acid, 4,4'-[1,2-ethanediylbis(thio)]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 412933-43-8 CAPLUS
CN 2-Butanesulfonic acid, 4,4'-[1,2-ethanediylbis(thio)]bis[2-methyl- (9CI) (CA INDEX NAME)



RN 412933-44-9 CAPLUS
CN Butanal, 4,4'-[1,2-ethanediylbis(thio)]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 412933-45-0 CAPLUS
CN Butanoic acid, 4,4'-[1,2-ethanediylbis(thio)]bis[2,2-dimethyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 412933-46-1 CAPLUS
CN Butanoic acid, 4,4'-[1,2-ethanediylbis(thio)]bis[2,2-dimethyl-, diphenyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:293607 CAPLUS
DOCUMENT NUMBER: 136:325232
TITLE: Preparation of sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
INVENTOR(S): Dasseux, Jean-Louis H.; Oniciu, Carmen Daniela
PATENT ASSIGNEE(S): Esperion Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 262 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030882	A2	20020418	WO 2001-US31871	20011011
WO 2002030882	C2	20030220		
WO 2002030882	A3	20030925		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2425678	AA	20020418	CA 2001-2425678	20011011
AU 2002011667	A5	20020422	AU 2002-11667	20011011
EP 1366024	A2	20031203	EP 2001-979735	20011011
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004531459	T2	20041014	JP 2002-534270	20011011

PRIORITY APPLN. INFO.: US 2000-239105P P 20001011
WO 2001-US31871 W 20011011

OTHER SOURCE(S): MARPAT 136:325232

AB Title compds. W1ZmSOGSOZmW2 (I) [wherein Z = independently CH2, CH:CH, or C6H4; m = independently 1-9; when Z = C6H4, m = 1; G = (CH2)x, CH2CH:CHCH2, CH:CH, CH2C6H4CH2, or C6H4; x = 2-4; W1 and W2 = independently CR1R2(CH2)nY, tetrahydro(oxo)pyranyl(oxy), oxooxetanyl, tetrahydrooxofuranyl, etc.; CR1R2(CH2)cCR3R4(CH2)nY, or CR1R2(CH2)cV; n = 0-4; c = 1-2; R1 and R2 = independently alkyl, alkenyl, alkynyl, Ph, or benzyl; or when one or both of W1 and W2 = CR1R2(CH2)cCR3R4Y, then R1 and R2 can both be H; R3 = H, alkyl, alkenyl, alkynyl, alkoxy, Ph, benzyl, Cl, Br, NO2, or CF3; R4 = OH, alkyl, alkenyl, alkynyl, alkoxy, Ph, benzyl, Cl, Br, CN, NO2, or CF3; Y = OH, CO2H, CHO, CO2R5, SO3H, mono-, di-, or triphosphate, dioxo- or dithioxohexahydrothieno[3,2-c]pyridinyl, sulfamoyl, tetrazolyl, hydroxyoxazolyl, hydroxypyranonyl, substituted imidazolidinedionyl, etc.; R5 = (un)substituted alkyl, alkenyl, alkynyl,

412953-15-2P 412953-16-3P 412953-17-4P
412953-18-5P 412953-19-6P 412953-20-9P
412953-21-0P 412953-22-1P 412953-23-2P
412953-24-3P 412953-26-5P 412953-28-7P
412953-29-8P 412953-30-1P 412953-31-2P
412953-32-3P 412953-33-4P 412953-34-5P
412953-35-6P 412953-36-7P 412953-37-8P
412953-38-9P 412953-39-0P 412953-40-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfoxide and bis-sulfoxide compds. as for cholesterol management and related uses)

RN 412951-74-7 CAPLUS
CN 2-Butanol, 4,4'-[1,3-propanediylbis(sulfinyl)]bis[2-methyl- (9CI) (CA INDEX NAME)



RN 412951-75-8 CAPLUS
CN 1-Butanol, 4,4'-[1,3-propanediylbis(sulfinyl)]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 412951-76-9 CAPLUS
CN Butanoic acid, 4,4'-[1,3-propanediylbis(sulfinyl)]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 412951-77-0 CAPLUS
CN Butanal, 4,4'-[1,3-propanediylbis(sulfinyl)]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 412951-78-1 CAPLUS
CN Butanoic acid, 4,4'-[1,3-propanediylbis(sulfinyl)]bis[2,2-dimethyl-,



RN 412953-39-0 CAPLUS
CN 2-Imidazolidinone, 1,1'-[1,3-propanediylbis[sulfinyl(2,2-dimethyl-5,1-pentanediyl)]]bis[3-ethyl-5-thioxo- (9CI) (CA INDEX NAME)



RN 412953-40-3 CAPLUS
CN 1-Pentanol, 5,5'-[1,2-ethanediylbis(sulfinyl)]bis[3,3-dimethyl- (9CI) (CA INDEX NAME)



L6 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:138052 CAPLUS
DOCUMENT NUMBER: 136:330461
TITLE: Aggregation Properties of a Novel Class of Cationic Gemini Surfactants Correlate with Their Efficiency as Gene Transfection Agents
AUTHOR(S): Jennings, Kevin H.; Marshall, Ian C. B.; Wilkinson, Michael J.; Kremer, Andreas; Kirby, Anthony J.; Camilleri, Patrick
CORPORATE SOURCE: Department of Analytical Chemistry, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK
SOURCE: Langmuir (2002), 18(6), 2426-2429
CODEN: LANGD5; ISSN: 0743-7463
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A group of cationic gemini surfactants comprising C12 saturated hydrocarbon tails and a short peptide headgroup with one or more basic amino acid residues show differences in their aggregation properties when dissolved in water and adsorbed onto carbon/Formgvar coated grids or freshly cleaved mica. A correlation was observed between surfactant morphol. and transfection efficiency. The surfactants that formed arrays or fibrils were ineffective as transfection agents in CHO-K1 cells, while those lacking these features were highly effective.
IT **307351-28-6 307351-29-7 307351-30-0 307351-32-2 307351-33-3**

RL: PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(aggregation properties of a novel class of cationic gemini surfactants correlate with their efficiency as gene transfection agents)

RN 307351-28-6 CAPLUS
CN L-Serinamide, 2,2'-(1,2-ethanediyl)bis[(2S)-2,4-diaminobutanoyl-L-cysteinyl-N-dodecyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 307351-29-7 CAPLUS
CN L-Serinamide, 3,3'-(1,2-ethanediyl)bis[L-lysyl-L-seryl-L-cysteinyl-N-dodecyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:795681 CAPLUS

DOCUMENT NUMBER: 132:35606
TITLE: Preparation of multibinding piperidinylindole derivatives as therapeutic agents that modulate 5-HT receptors
INVENTOR(S): Marquess, Daniel; Griffin, John H.; Choi, Seok-Ki
PATENT ASSIGNEE(S): Advanced Medicine, Inc., USA
SOURCE: PCT Int. Appl., 190 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 31
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964044	A1	19991216	WO 1999-US12751	19990607
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2318894	AA	19991216	CA 1999-2318894	19990604
AU 9945435	A1	19991230	AU 1999-45435	19990604
EP 1003540	A1	20000531	EP 1999-928344	19990604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002517457	T2	20020618	JP 2000-553099	19990604
CA 2318055	AA	19991216	CA 1999-2318055	19990607
CA 2318286	AA	19991216	CA 1999-2318286	19990607
CA 2319068	AA	19991216	CA 1999-2319068	19990607
CA 2319159	AA	19991216	CA 1999-2319159	19990607
CA 2319174	AA	19991216	CA 1999-2319174	19990607
CA 2319175	AA	19991216	CA 1999-2319175	19990607
CA 2319496	AA	19991216	CA 1999-2319496	19990607
CA 2319751	AA	19991216	CA 1999-2319751	19990607
CA 2319756	AA	19991216	CA 1999-2319756	19990607
CA 2321170	AA	19991216	CA 1999-2321170	19990607
CA 2321273	AA	19991216	CA 1999-2321273	19990607
AU 9944234	A1	19991230	AU 1999-44234	19990607
AU 9944253	A1	19991230	AU 1999-44253	19990607
AU 9944265	A1	19991230	AU 1999-44265	19990607
AU 9945491	A1	19991230	AU 1999-45491	19990607
AU 9945520	A1	19991230	AU 1999-45520	19990607
AU 9946727	A1	19991230	AU 1999-46727	19990607
AU 9946751	A1	19991230	AU 1999-46751	19990607
AU 9946752	A1	19991230	AU 1999-46752	19990607
AU 9946754	A1	19991230	AU 1999-46754	19990607
EP 1019360	A1	20000719	EP 1999-930123	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1080080	A1	20010307	EP 1999-930158	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1083917	A1	20010321	EP 1999-927291	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1083918	A1	20010321	EP 1999-927317	19990607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

multibinding compds., formed from two piperidinylindole derivs. and a difunctional linker, were prepared For example, condensation of 5-(4-fluorobenzoyl)amino-3-(piperidin-4-yl)-1H-indole with 1,2-dibromoethane at 72° in DMF, after workup and chromatog., yielded the dimer II. Compds. of this invention are useful in the treatment of migraine, headache, itch, motion sickness, depression, emesis, memory loss, anxiolytic disorders, obesity, gastrointestinal disorders, and irritable bowel syndrome (no data). The multibinding compds. provide greater biol. and/or therapeutic effects than the aggregate of the unlinked ligands due to their multibinding properties (no data). Combinatorial arrays, methods of synthesis, and methods of assaying the dimeric and multimeric compds. are also embodied by the invention.

IT **252355-36-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of multibinding piperidinylindole derivs. as therapeutic agents that modulate 5-HT receptors and are useful for the treatment of migraine)

RN 252355-36-5 CAPLUS

CN Acetamide, 2,2'-[1,2-ethanediylbis(thio)]bis[N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:390415 CAPLUS
DOCUMENT NUMBER: 131:49469
TITLE: Peptide-based gemini compounds
INVENTOR(S): Camilleri, Patrick; Kremer, Andreas; Rice, Simon Quentyn John
PATENT ASSIGNEE(S): SmithKline Beecham PLC, UK
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9929712	A1	19990617	WO 1998-GB3652	19981208
W: CA, JP, US				

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:276769 CAPLUS
DOCUMENT NUMBER: 126:343884
TITLE: Preparation of dimeric hemoregulatory peptides
INVENTOR(S): Bhatnagar, Pradip K.; Huffman, William F.; Talmadge, James E.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: U.S., 32 pp., Cont.-in-part of U.S. Ser. No. 819,024, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 5620957	A	19970415	US 1993-1905		19930108
US 5776900	A	19980707	US 1995-453123		19950530
PRIORITY APPLN. INFO.:			US 1989-380578	B2	19890714
			US 1990-547730	B2	19900702
			US 1992-819024	B2	19920110
			US 1993-1905	A1	19930108

OTHER SOURCE(S): MARPAT 126:343884
GI



I

AB The invention provides dimeric peptides I [Y1 = CH2, S; Y2 = CH2, S; x = 0-4; m = 0-2; n = 0-2; A = pGlu, Pro, Gln, Tyr, Glu, heterocyclic carboxylic acid, cyclohexanecarboxylic acid; B = Ser, Thr, Glu, Tyr, Asp; C = Glu, Tyr, Asp, Ser, Ala, Phe, His, Ile, Leu, Met, Tyr, Thr, Trp, Nle, allo-Thr, Gln, Asn, Val, Pro, Gly, Lys, β-Ala, Sar; D = Lys, Arg, Tyr, N-methylarginine, Asp, Orn, Ser, Ala, Phe, His, Ile, Leu, Met, Thr, Trp, Nle, allo-Thr, Gln, Asn, Val, Pro, Gly, Lys, β-Ala, Sar; diaminohexynoic acid, or the carboxamide or hydroxymethyl derivative thereof; E = Glu, Asp, Tyr, bond; F = Tyr, bond], with provisos, or a pharmaceutically acceptable salt thereof. I have hemoregulatory activities and can be used to stimulate hematopoiesis and for the treatment of viral, fungal and bacterial infectious diseases.

IT **134143-37-6P 134143-38-7P 134143-39-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dimeric hemoregulatory peptides)

RN 134143-37-6 CAPLUS
CN L-Lysine, 4,4'-(1,3-propanediyl)bis[5-oxo-L-prolyl-L-α-glutamyl-L-α-aspartyl-L-cysteinyl- (9CI) (CA INDEX NAME)

PAGE 1-B



RN 134143-39-8 CAPLUS
CN L-Lysine, 4,4'-(1,4-butanediyl)bis[5-oxo-L-prolyl-L-α-glutamyl-L-α-aspartyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L6 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:165101 CAPLUS
DOCUMENT NUMBER: 126:162326
TITLE: Copolymer soft intraocular lenses having high

refractive indexes
INVENTOR(S): Kyo, Takeshi
PATENT ASSIGNEE(S): Hoya Corp, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08336581	A2	19961224	JP 1995-147065	19950614
JP 3429393	B2	20030722		

PRIORITY APPLN. INFO.: JP 1995-147065 19950614

AB Copolymer soft intraocular lenses having high refractive indexes are prepared with S-containing bifunctional monomers such as [CH2:CHCO2(CH2)6CO2CH2CH2SCH2-]2, benzoic acid unsatd. ester monomers and/or (meth)acrylate monomers.

IT **186963-12-2P 186963-18-8P**
RL: DEV (Device component use); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(polymer soft intraocular lenses having high refractive indexes)

RN 186963-12-2 CAPLUS
CN Benzoic acid, ethenyl ester, polymer with 6-[(1-oxo-2-propenyl)oxy]hexyl 10,19-dioxo-11,18-dioxa-4,7-dithiaheneicos-20-enoate (9CI) (CA INDEX NAME)

CM 1

CRN 142032-98-2
CMF C26 H42 O8 S2

PAGE 1-A



PAGE 1-B



CM 2

CRN 769-78-8
CMF C9 H8 O2



RN 186963-18-8 CAPLUS

CN Benzoic acid, ethenyl ester, polymer with 2-ethylhexyl 2-propenoate and 6-[(1-oxo-2-propenyl)oxy]hexyl 10,19-dioxo-11,18-dioxa-4,7-dithiaheneicos-20-enoate (9CI) (CA INDEX NAME)

CM 1

CRN 142032-98-2
CMF C26 H42 O8 S2

PAGE 1-A



PAGE 1-B



CM 2

CRN 769-78-8
CMF C9 H8 O2



CM 3

CRN 103-11-7
CMF C11 H20 O2



L6 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:546098 CAPLUS
DOCUMENT NUMBER: 125:177479
TITLE: Dental polymers with improved durability and wear- and water-resistances
INVENTOR(S): Irisato, Yoshihiro; Kanemura, Yoshinobu; Nagata, Teruyuki
PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08157320	A2	19960618	JP 1994-301996	19941206

PRIORITY APPLN. INFO.: JP 1994-301996 19941206

AB Dental polymer materials (composite resins) with improved durability and wear- and water-resistances comprise ≥3 S-containing (meth)acrylic esters and other monomers and have refractive indexes of ≥ 1.56. Thus, copolymer of S[Ph-SCH2CH(OH)CH2COO2C(CH3):CH2]2, camphor quinone, and N,N-dimethylethyl methacrylate was prepared and its refractive index was determined to be 1.631.

IT **180796-18-3P**
RL: SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(dental polymers with improved durability and wear- and water-resistances)

RN 180796-18-3 CAPLUS

CN 2-Propenoic acid, 2-methyl-, 2-(dimethylamino)ethyl ester, polymer with 1,2-ethanediylbis[thio(2-hydroxy-3,1-propanediyl)] di-2-propenoate and 1,7,7-trimethylbicyclo[2.2.1]heptane-2,3-dione (9CI) (CA INDEX NAME)

CM 1

CRN 180796-17-2
CMF C14 H22 O6 S2

PAGE 1-A



PAGE 1-B

$=CH_2$

CM 2

CRN 10373-78-1
CMF C10 H14 O2



CM 3

CRN 2867-47-2
CMF C8 H15 N O2



L6 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:345411 CAPLUS
DOCUMENT NUMBER: 125:33322
TITLE: Preparation of α,α,α'α'-tetrachlorodicarboxylic acid antidiabetic agents
INVENTOR(S): Voss, Edgar; Pill, Johannes; Freund, Peter
PATENT ASSIGNEE(S): Boehringer Mannheim Gmbh, Germany
SOURCE: Ger. Offen., 6 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4436578	A1	19960418	DE 1994-4436578	19941013
WO 9611901	A1	19960425	WO 1995-EP3980	19951010
W: AU, BG, BR, BY, CA, CN, CZ, EE, FI, HU, JP, KR, KZ, MX, NO, NZ, PL, RO, RU, SI, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9538406	A1	19960506	AU 1995-38406	19951010
PRIORITY APPLN. INFO.:			DE 1994-4436578 A	19941013
			WO 1995-EP3980 W	19951010

OTHER SOURCE(S): MARPAT 125:33322
AB The title compds. HO2CCCl2ABA1CCl2CO2H [A, A1 = (un)branched C1-10 alkylene; B = phenylene, cyclohexylidene, S, O, (un)substituted NH], useful for the treatment of metabolic disorders [e.g., diabetes mellitus (no data)], are prepared Thus, HCl2CCO2H was reacted with LiN(Pr-iso)2 and 1,4-bis(3-bromopropyl)benzene, producing 5-[4-(4-carboxy-4,4-dichlorobutyl)phenyl]-2,2-dichloropentanoic acid, m.p. 239-240°, in 68% yield.
IT **177429-71-9P**
RL: SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of α,α,α'α'-tetrachlorodicarboxylic acid antidiabetic agents)
RN 177429-71-9 CAPLUS
CN Heptanoic acid, 7,7'-[1,3-propanediylbis(thio)]bis[2,2-dichloro- (9CI) (CA INDEX NAME)



L6 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:468609 CAPLUS
DOCUMENT NUMBER: 122:237789
TITLE: Methods of enhancing bioactivity of chemokines
INVENTOR(S): Pelus, Louis M.; Bhatnagar, Pradip Kumar; King, Andrew Garrison; Balcarek, Joanna Maria
PATENT ASSIGNEE(S): SmithKline Beecham Corp., USA

SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9429341	A1	19941222	WO 1994-US6264	19940603
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 713495	A1	19960529	EP 1994-920701	19940603
EP 713495	B1	20031105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08511167	T2	19961126	JP 1995-501970	19940603
AT 253637	E	20031115	AT 1994-920701	19940603
EP 1378522	A2	20040107	EP 2003-76813	19940603
EP 1378522	A3	20040204		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI				
PT 713495	T	20040331	PT 1994-920701	19940603
ES 2210255	T3	20040701	ES 1994-920701	19940603
US 6080398	A	20000627	US 1996-557142	19960305
US 6399053	B1	20020604	US 1999-467160	19991220
US 6447766	B1	20020910	US 1999-467155	19991220
US 2004057925	A1	20040325	US 2002-146182	20020515

PRIORITY APPLN. INFO.:

US 1993-73800	A	19930608
EP 1994-920701	A3	19940603
WO 1994-US6264	W	19940603
US 1995-547262	B2	19951024
US 1996-557142	A3	19960305
WO 1996-US17074	A2	19961024
US 1997-999804	B1	19971126
US 1999-467160	A3	19991220

OTHER SOURCE(S): MARPAT 122:237789

AB Methods of increasing the biol. activity of KC, gro-α, gro-β, and gro-γ proteins for >1 log better than the full-length protein by truncating and modifying the proteins are disclosed. Preparation of murine KC protein and human gro-β protein by recombinant or synthetic method was shown. A pharmaceutical composition containing the modified peptides in monomeric or multimeric forms for treating inflammatory condition and stimulating growth or differentiation of bone marrow cells is claimed. An antibody capable of selectively binding to a modified chemokine is also claimed. A compound, ABCE-NHCH(CO-FD)(CH2)mY1(CH2)xY2(CH2)nCH(CO-FD)NH-ECBA (Y1, Y2=CH2, S; X=0.apprx.4; m, n=0.apprx.2; A.apprx.F=(modified)amino acid residue), for inducing a hematopoietic synergistic factor in mammal is also disclosed.

IT **162010-97-1P**
RL: SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(hematopoietic synergistic factor-inducing peptide and its synthesis)

RN 162010-97-1 CAPLUS

CN L-Lysine, 4,4'-(1,3-propanediyl)bis[5-oxo-L-prolyl-L-α-glutamyl-L-α-aspartyl-N-[(1,1-dimethylethoxy)carbonyl]-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L6 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:401296 CAPLUS
DOCUMENT NUMBER: 122:170194
TITLE: Blood pool imaging composition and method of its use
INVENTOR(S): Bogdanov, Alexei A.; Weissleder, Ralph; Brady, Thomas J.; Callahan, Ronald
PATENT ASSIGNEE(S): General Hospital Corp., USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9428940	A1	19941222	WO 1994-US6282	19940603
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5605672	A	19970225	US 1993-74319	19930609
EP 711178	A1	19960515	EP 1994-919353	19940603
EP 711178	B1	20030521		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
AT 240748	E	20030615	AT 1994-919353	19940603

ES 2197164 T3 20040101 ES 1994-919353 19940603
PRIORITY APPLN. INFO.: US 1993-74319 A 19930609
WO 1994-US6282 W 19940603

AB The invention features a method of blood pool imaging which utilizes an imaging agent which can be easily labeled with a radioactive isotope and injected into a patient. The imaging agent is a covalent conjugate of a polymeric carrier, protective groups, and chelating groups. The imaging agent is preferably provided in the form of a blood pool imaging composition, which includes an imaging agent of the invention, a buffer and a reducing compound A radioactive isotope is added to the blood pool imaging composition to label the imaging agent, and the composition containing the labeled imaging agent is injected i.v. into a patient.

IT **14344-49-1**
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(blood pool imaging composition)

RN 14344-49-1 CAPLUS
CN L-Cysteine, S,S'-1,2-ethanediylbis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1973:106131 CAPLUS
DOCUMENT NUMBER: 78:106131
TITLE: Antineoplastic action of vinyl sulfones and their possible precursors
AUTHOR(S): Pol'kina, R. I.; Remizov, A. L.; Petrov, A. S.
CORPORATE SOURCE: N. N. Petrov Res. Inst. Oncol., Leningrad, USSR
SOURCE: Voprosy Onkologii (1973), 19(1), 82-8
CODEN: VOONAW; ISSN: 0507-3758
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB In vitro and in vivo (rats and mice) tests on sarcomas 180, 37, and LiO-1, ascitic lymphosarcoma, solid and ascitic Ehrlich tumors, and rat ovarian ascites tumor showed that vinyl sulfones have little value as antitumor agents. Acetoxyethylsulfones and other precursors which can be readily converted into vinyl sulfones by β-eliminations showed cytotoxic action (similar to that of sarcolysine [531-76-0]) during direct contact with tumor cells. When administered i.p. in therapeutic doses (0.1-0.2 LD50) daily for 12 days these compds. had almost no general toxic action and no adverse effect on hemopoiesis. Bis(2-acetoxyethylsulfonyl)methane [39227-09-3] was the strongest antitumor agent of 16 vinylsulfone pecursors studied.

IT **7426-03-1 7484-34-6 41123-71-1**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(neoplasm inhibitors)

RN 7426-03-1 CAPLUS
CN Ethanol, 2,2'-[1,4-butanediylbis(sulfonyl)]bis- (9CI) (CA INDEX NAME)



RN 7484-34-6 CAPLUS
CN Ethanol, 2,2'-[1,2-ethanediylbis(sulfonyl)]bis- (9CI) (CA INDEX NAME)



RN 41123-71-1 CAPLUS
CN Ethanol, 2,2'-[1,3-propanediylbis(sulfonyl)]bis- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 13:17:38 ON 25 OCT 2005)

FILE 'REGISTRY' ENTERED AT 13:17:49 ON 25 OCT 2005
L1 STRUCTURE UPLOADED
L2 24 S L1
L3 STRUCTURE UPLOADED
L4 7 S L3
L5 1302 S L3 FULL

FILE 'CAPLUS' ENTERED AT 13:33:33 ON 25 OCT 2005
L6 18 S L5/THU

=> d l3
L3 HAS NO ANSWERS
L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=>